Quarterly Result14 Nov 2026, 09:30 pm
ANG Lifesciences Approves Unaudited Financial Results for Q2 FY27
AI Summary
ANG Lifesciences India Ltd announced the approval of its unaudited financial results for the quarter and half-year ended September 30, 2026. The Board of Directors also noted the appointment of Mrs. Preeti Sarin as an Additional Independent Director for a term of five years, subject to shareholder approval. Mrs. Sarin meets the criteria for independence as per the Companies Act, 2013 and SEBI Listing Regulations.
Key Highlights
- Unaudited financial results for Q2 FY27 approved.
- Half-year financial results ended September 30, 2026, approved.
- Mrs. Preeti Sarin appointed as Additional Independent Director.
- Director appointment is for a five-year term.
- Appointment subject to shareholder approval.
Price Impact
More from ANG